Introduction
There are multiple examples of targeted anticancer drugs that are clinically effective in targeting different cancers driven by the same oncogene including the recent report of the activity of TRK inhibitors across a wide range of tumors driven by TRK fusions (1) . However, there is emerging evidence related to context specificity where differences in signaling in different tumor types driven by the same oncogene can result in disparate clinical outcomes; for example, the BRAF inhibitor, vemurafenib, causes clinical responses in patients with V600E mutant BRAF-driven melanoma (2) but not colorectal cancer (3) . This has been attributed to differences in EGFR signaling between the two tumor types (4) . There have been detailed studies of down-stream signaling patterns of KRASmutated (KRAS MT) mutated non-small cell lung (NSCLC), pancreatic ductal carcinoma (PDAC) and colorectal cancer (CRC) to define patterns of signaling, feedback loops and optimal combination therapy (7) (8) (9) (10) . In the light of emerging evidence of context specificity of drug response in cancer (3, 4) and the reports that patients with KRAS MT NSCLC and CRC respond differentially when treated with combinations of MEK and PI3K pathway inhibitors (11, 12) we aimed to study 6 differences in dynamic signaling patterns in three diseases with frequent KRAS mutations ie NSCLC, PDAC and CRC.
Mutations in the oncogene
We chose to study differences in signaling patterns in 30 KRAS MT cell lines (10 NSCLC, 10 CRC and 10 PDAC) and 10 KRAS MT cells isolated from patients with malignant effusions. It is known that differences in the type of KRAS mutations between these tumor types do occur, for example, G12C mutations occur more frequently in KRAS mutated NSCLC compared to CRC (5) . The different KRAS mutations in our cell line panel are listed in Supplementary Table S1 . An antibodybased platform was used to screen changes in 50 phosphoproteins which are relevant to KRAS signaling and are related to targets of the drugs used as probes ( Figure 1 ). We exposed the cell lines to clinically relevant concentrations of 7 targeted anticancer drugs: AZD5363 (13) (AKT inhibitor), everolimus (m-TOR inhibitor), gefitinib (EGFR inhibitor), luminespib/NVP-AUY922 (14) (HSP90 inhibitor), pictilisib/GDC-0941 (15) (PI3K inhibitor), trametinib (MEK inhibitor), vemurafenib (BRAF inhibitor). We chose these drugs as tools as they were known to inhibit signaling nodes related to KRAS signaling and/or where KRAS mutations were known to effect sensitivity to the drug. Further, all these drugs had been used in the clinic and it was possible to use concentrations of the drugs that were clinically relevant. We used equimolar drug concentrations across cell lines and patient samples rather than individual G I50 concentrations across all samples as we were focussed on using clinically relevant concentrations and it was not possible to determine GI 50 of drugs in cells isolated from ascites of patients as we did not establish cell lines from these samples. We planned to validate any interesting findings in more detailed experiments.
7 A second set of antibodies, targeting phosphorylated versions of the antibodies from the first set, were biotinylated (Biotin Type A conjugation kit, ab102865, Abcam, Cambridge, UK). This home-grown assay followed the Millipore protocol; however, 9 during the optimization process it was found that small amounts of unbound biotin in the secondary antibody mix were binding directly to protein, increasing background.
Materials and Methods
To offset this as much as possible the secondary antibody was added directly postprimary incubation and unbound protein was only washed off post-secondary antibody incubation.
Phosphoprotein levels were measured on the Luminex 200 system utilising xPONENT v3.1 software.
We attempted to quality control our Luminex platform. Three test cell lines (A2780, HT29 and NCI-H520) were run in triplicate and each repetition was run across five separate 96-well plates. All plates were run in a single sitting to avoid inter-daily fluctuations. Baseline phospho-protein levels were measured and the coefficient of variation (CV) per analyte was calculated. There was considerable variation in the assays with the CV being >30% in at least one of the three cell lines in 12 of the 55 analytes tested. The CV of phosphoproteins of interest such as p-MEK and p-AKT was <10% and <20%, respectively, in all three cell lines tested during the validation (Supplementary Table S2 ).
Each Millipore Mapmate kit provided positive and negative lysate controls for each analyte (as listed in the manufacturer's manual). These were all run once at the start of the project. A protein concentration titration was also carried out to assess the appropriate amount of protein to use in each assay. Positive controls for the homegrown bead set were found via a literature search and were used in the optimization process.
The assay platform continues to be in development and would not meet the individual total proteins is that this would very significantly increase the cost and complexity of the screening assay.
Interpretation of phosphoproteomic data
All phosphoproteomic data were normalized to GAPDH. Importantly, for each cell line, three samples of control and one sample for each drug treatment was set up. A standard deviation was calculated for each control and if the drug treated sample had a value more than 2 standard deviations above it was classified as 'increased'
and if 2 standard deviations below it was classified as 'decreased'. If it was within 2 standard deviations above or below the control it was considered unchanged. We chose to use dichotomous, increased, decreased or no change outputs as we had not validated the linearity of the absolute changes in phosphoprotein in our assays. 11 We ran only controls and did not treat samples in triplicate because of the cost but repeated specific experiments in triplicate to validate any interesting changes seen.
For the purpose of analysis by logistic regression, only individual analytes which were considered to be significantly increased or decreased (2 standard deviations above or below the mean control) compared to control were used. These phosphorylation changes in cell lines from one tumor type were compared to the other two groups e.g. NSLC Vs CRC and PDAC, CRC Vs NSCLC and PDAC, PDAC Vs NSCLC and CRC using the generalized linear models function in R to compute logistic regression (RStudio, V1.1.383, RStudio,Inc). False discovery rate was corrected for via the Benjamini-Hochberg (BH) procedure (RStudio) and only changes that were significant after BH correction are mentioned in Figure 3 .
Quantification of p-AKT and AKT by ELISA
Cells were lysed and phospho/Total AKT levels were measured using a phospho (ser473)/Total AKT whole cell lysate kit (Meso Scale Discovery, Rockville, MD, USA, K15100D-1) following manufacturers guidelines.
Cytotoxicity and combination studies
Growth inhibition was assessed via standard 72-hour sulforhodamine B assays by previously described methods (17) . 
Results

Differences between mutations and baseline m-RNA signatures of cell lines
Phosphoproteomic screen
Interestingly, p-MEK levels increased in more than 50% of cell lines in cells exposed to the PI3K inhibitor, pictilisib, AKT inhibitor, AZD5363, EGFR inhibitor, gefitinib, BRAF inhibitor, vemurafenib, and HSP90 inhibitor, luminespib. p-ERK levels were increased in more than 50% of cell lines upon exposure to the BRAF inhibitor, vemurafenib, AKT inhibitor, AZD5363, and EGFR inhibitor, gefitinib (Supplementary Table S3 ). These results suggest increased activation of MEK is a relatively common re-wiring event across multiple different drugs in the cell line panel tested.
There were similarities between changes caused by drugs targeting a defined signaling pathway, for example, more than 50% of all the 30 cell lines showed reduction of p-S6 when exposed to pictilisib, AZD5363 and everolimus all targeting the PI3K pathway. There were differences in phosphorylation of proteins in drugs targeting the PI3K pathway, for example, p-AKT levels were increased in more than 50% of cell lines exposed to AZD5353 but not pictilisib or everolimus. The increase 13 in phosphorylation of AKT despite inhibition of the target is known to be due to change in conformation of the drug target.
We then tested to see if changes in each analyte were different in the three different tumor types when exposed to an individual drug using logistic regression and correcting for multiple testing (Figure 3) . A total of 39 changes in phosphorylation was considered significantly different across different tumor types (Table 1) .
Interestingly, a significantly lower number of CRC cell lines showed a reduction in phosphorylation of AKT Ser473 when exposed to pictilisib at a clinically relevant, equimolar concentration compared to NSCLC and PDAC cell lines (P = 0.037).
Conversely, p-AKT Ser473 levels were reduced in NSCLC cell lines exposed to pictilisib compared to PDAC and CRC, although this was not statistically significant.
Further, when exposed to pictilisib, significantly fewer NSCLC cell lines showed an increase in phosphorylation of MEK compared to CRC and PDAC cell lines (P = 0.036). We went on to further validate the findings of differential phosphoprotein changes between NSCLC, CRC and PDAC cell lines when exposed to pictilisib.
We analyzed differences between phosphoprotein changes caused by all seven drugs by unbiased clustering and there were no significant differences between types of KRAS mutation (Supplementary Note). 14 
Validation of findings related to dynamic signaling changes of the pan-PI3K inhibitor, pictilisib
We chose 9 cell lines (3 each of CRC, PDAC and NSCLC) from the original panel to validate our results, exposing them for both 1 hr. We conducted the experiments in triplicate allowing more detailed assessment of fold change compared to threshold based binary representations used for logistic regression in the initial 1hr screen.
The patterns of non-reduction of p-AKT in CRC cell lines and no increase in p-MEK levels in the NSCLC cell lines were recapitulated at 1 hr of exposure to pictilisib and technically validated our findings in the larger screen ( Figure 4A ). We also used a further assay (ELISA) to quantify p-AKT Ser473 and total AKT at the 1 hr time-point and the CRC cell lines exposed to pictilisib showed a lesser reduction of p-AKT Ser473 normalized to total AKT compared to NSCLC cell lines (Supplementary Figure 3) .
We also determined the GI 50 of pictilisib and another pan-PI3K inhibitor, buparlisib, exposing the 9 cell lines to increasing concentrations of pictilisib and buparlisib for 1 hr to study changes in p-AKT and p-MEK. Changes in phosphorylation caused by pictilisib were concordant with that of buparlisib, suggesting that phosphoprotein changes were not due to the off-target effects of pictilisib ( Figure 4B ). It was, however, noted that p-MEK levels increased in the NSCLC cell line N1944 in Figure   4B as increasing while this was not the case in Figure 3 and Figure 4A . The concentration of pictilisib used in experiments 3 and 4A was 96.3 nM, while concentrations of pictilisib used in Figure 4B were GI 50 and x5 GI 50, which was considerably higher (Supplementary Table 4 ) and this may account for this difference. 15 We studied p-MEK and p-AKT levels in cancer cells isolated from serous effusions (pleural effusions and ascites) in 10 patients with KRAS mutant cancers (3 NSCLC and 7 CRC) exposed to pictilisib for 1 hr as we had done in the 30 cell line screen.
We found the increase in the p-MEK levels was significantly raised in 3/7 samples of cells isolated from patients with CRC as opposed to 0/3 samples of cells isolated form NSCLC. No significant reduction of p-AKT was seen in either CRC or NSCLC samples ( Figure 4C ). The number of samples were not sufficient for statistical analysis however the experiment provided proof of concept that it is possible to conduct ex-vivo assays on cancer cells freshly isolated from cancer patients.
Discussion
To our knowledge, this is the first report to study the differences in dynamic signaling patterns in KRAS MT cell lines in an attempt to study context specificity of tumors of origin.
Antibody-based phosphoprotein platforms have been used to study signaling output in cancer cells exposed to drugs, with reverse-phase protein arrays being one of the more established platforms (18) . We used the antibody-bead based Luminex platform (19) . The drugs used as probes were anticancer drugs that were either licensed (everolimus, gefitinib, trametinib, vemurafenib) or in phase II studies (AZD5363, luminespib and pictilisib). We chose to use clinically relevant concentrations of these drugs at human Cmax and exposed the cell lines and patient samples to these concentrations for 1 hr. Most phosphorylation changes occur early and so we chose a 1-hr time-point to reflect this, as well as the fact that concentrations surrounding Cmax could be maintained for 1 hr. Our aim was to study 16 differences in signal transduction at early time-points. We acknowledge that rewiring of signal transduction may change at later time-points which we did not study.
Further, we attempted to standardize the treatment conditions by exposing cells to drugs at 80% confluence. The cells were exposed to drugs for 1 hour so the drugs are unlikely to cause major differences in cell density due to cell death or growth inhibition, however it was not possible to rule out the effects of contact inhibition on signaling in individual cell lines. We did not establish cell lines form each patient sample and cells derived from ascites or pleural effusions were EpCam separated and exposed to drugs for 1 hr in suspension. It was not possible to ascertain the contribution of differences in tissue culture conditions i.e adherent vs suspension in the results while comparing cell lines and patient samples. The importance of PI3K signaling in KRAS MT CRC, NSCLC and PDAC has been described previously (20) .
Co-existence of activating PIK3CA mutations with KRAS mutations in the general population of NSCLC, CRC and PDAC is rare (21, 22) . However, the co-existence of CRC cell lines has not been described previously.
We went on to validate specific changes in cells seen in response to pictilisib by repeat experiments in triplicate. We also confirmed that these changes in p-MEK and p-AKT occurred when a second pan-PI3K inhibitor was used, which suggested that the phosphoprotein changes are not due to the off-target effects of pictilisib.
Interestingly, in cancer cells isolated from patients with KRAS MT , NSCLC did not show activation in p-MEK, while some of the samples isolated from patients with KRAS MT CRC did. The number of samples studied did not allow robust statistical analysis however shows proof of concept that such tissue can be used to study changes in phosphoproteins.
The context specificity of oncogenes to induce cancer has been described (25) . In the setting of KRAS MT cancers, there is increasing evidence that tissue of origin also 18 dictates metabolism of branched chain amino acids (26) . The signaling patterns within cancers cells are influenced by surrounding stromal cells as shown in KRAS mutant cancer cells such PDAC (27) . It is possible that stromal differences in diverse organs lead to context specificity of KRAS mutated cancers. The findings in the current study of signaling in cancer cells did not take stromal influences into consideration and could be considered as a weakness in the experimental design.
However, our findings are of particular significance as they suggest inherent differences in signaling output in KRAS mutant cancer cells sans stroma and may in part be responsible for context specificity of response to signaling inhibitors seen in clinical trials. Our study was confined to cell lines that had known KRAS mutations.
However, it was not possible to answer the interesting question relating to contextspecificity of signaling extending to non-KRAS mutant cell lines.
Context specificity is a critical facet that influences the precision medicine paradigm.
There is already evidence that this is clinically important to drug response, as has been exemplified by BRAF inhibitors (3, 4 Changes in phosphorylation of proteins that were increased or decreased upon exposure to different drugs but were significantly different from cells derived from different tumor types i.e. NSCLC, CRC and PDAC upon logistic regression corrected for multiple testing. Figures   Figure 1 The figure shows the network of interactions between the phosphoproteins studied in this project and the targets of the drugs used and KRAS. Targets of the drugs are shown as red nodes. 
Legends to
Results of phosphoproteomic screen
Changes in phosphorylation in cell lines exposed to targeted anticancer drugs. For each analyte, phosphorylation changes had to be first separated out into 'up regulated vs not'
and 'down-regulated vs not' giving binary '1/0' categories. Logistic regression compared the number of '1s' in one tumor type to the '1s' in the other two tumor types combined, repeated for each tumor/drug/analyte configuration and was corrected for multiple testing.
The color green and symbol -1 denotes that the levels of the phosphoprotein were 2 standard deviations below the control; the color red and symbol 1 denote levels of phosphoprotein that were 2 standard deviations above control and cells with no color and symbol 0 denote values between 2 standard deviations above and below control. Only changes that were significantly different between any of the three tumor types by logistic regression have been depicted. 
